Mira Pharmaceuticals Reports Preclinical Data of Ketamir-2 to Treat Depression


MIRA has reported preclinical data from the safety & efficacy study of Ketamir-2 vs traditional ketamine to treat depression & treatment-resistant depression (TRD) in male mice. The IND submission to the US FDA is anticipated in H2’24
Results depicted a dose-related increase in locomotor activity & travel speed with a trend favoring higher time spent in the arena center. Increased travel distance & speed were also seen with mice spending greater time in open arms of the maze, indicating reduced anxiety
Ketamir-2 further decreased swimming distances & speed, suggesting less behavioral despair & antidepressant effect, as well as immobility times. Traditional ketamine was inactive when administered at the highest dose possible

Ref: MIRA Pharmaceuticals | Image: MIRA Pharmaceuticals

Related News:- MIRA Pharmaceuticals & MIRALOGX Entered into an Exclusive Licensing Agreement for Ketamir-2

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com